Profile data is unavailable for this security.
About the company
Sansure Biotech Inc is a company mainly engaged in research and development, production and sales of diagnostic reagents and instruments. The Company's diagnostic reagent products are comprised of viral hepatitis series, reproductive tract infection and genetic series, pediatric infection series and nucleic acid blood screening series. The instrument products include automatic nucleic acid detection reaction system construction series and fluorescent polymerase chain reaction (PCR) monitoring and analysis software. The Company also provides related inspection services, including medical inspection and scientific research services which are provided for medical institutions.
- Revenue in CNY (TTM)1.20bn
- Net income in CNY384.73m
- Incorporated2008
- Employees2.01k
- LocationSansure Biotech IncNo.680 Lusong RoadHigh-Tech Industrial Development ZoneCHANGSHA 410205ChinaCHN
- Phone+86 73 188883176
- Fax+86 73 184223503
- Websitehttps://www.sansure.com.cn/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jiangsu Kanion Pharmaceutical Co., Ltd. | 4.87bn | 543.34m | 9.84bn | 5.44k | 18.11 | 1.83 | -- | 2.02 | 0.9342 | 0.9342 | 8.39 | 9.22 | 0.6915 | 3.50 | 6.92 | 895,523.30 | 7.82 | 6.68 | 10.54 | 9.49 | 72.55 | 74.02 | 11.31 | 10.28 | 2.23 | -- | 0.00 | 25.57 | 11.88 | 4.94 | 23.54 | 5.33 | -1.87 | 35.99 |
| Joinn Laboratories China Co Ltd | 2.33bn | -62.99m | 10.23bn | 2.50k | -- | 1.38 | -- | 4.39 | -0.0862 | -0.0862 | 3.12 | 10.75 | 0.23 | 0.6906 | 8.14 | -- | -0.6856 | 8.99 | -0.8219 | 11.07 | 39.46 | 46.76 | -2.98 | 32.01 | 3.51 | 0.9996 | 0.0079 | 23.79 | 4.78 | 42.20 | -63.04 | 29.66 | 8.21 | 23.46 |
| Bio-Thera Solutions Ltd | 711.46m | -370.90m | 10.33bn | 1.17k | -- | 9.45 | -- | 14.52 | -0.8957 | -0.8957 | 1.72 | 2.64 | 0.3099 | 0.9439 | 6.06 | 609,647.70 | -16.15 | -23.62 | -23.70 | -30.81 | 71.41 | 79.76 | -52.13 | -106.72 | 0.8258 | -367.55 | 0.3515 | -- | 54.86 | -- | 17.87 | -- | -3.78 | -- |
| Sansure Biotech Inc | 1.20bn | 384.73m | 10.68bn | 2.01k | 28.15 | 1.42 | -- | 8.88 | 0.6448 | 0.6448 | 2.06 | 12.77 | 0.1377 | 0.8274 | 1.41 | 599,646.90 | 4.14 | 26.74 | 4.69 | 30.97 | 74.82 | 67.47 | 30.06 | 42.01 | 7.94 | -- | 0.0589 | 22.40 | -84.39 | 27.12 | -81.22 | 121.89 | 64.08 | -- |
| Liaoning Chengda Biotechnology Co Ltd | 1.76bn | 420.34m | 10.91bn | 1.73k | 25.84 | 1.12 | -- | 6.19 | 1.01 | 1.01 | 4.26 | 23.41 | 0.1743 | 0.7061 | 1.61 | 1,016,911.00 | 4.16 | 10.63 | 4.27 | 11.01 | 81.48 | 85.74 | 23.87 | 39.56 | 20.80 | -- | 0.002 | 31.53 | -3.58 | 4.71 | -34.75 | -5.56 | 39.78 | -- |
| Jiangxi Tianxin Pharmaceutical Co Ltd | 1.80bn | 514.80m | 11.08bn | 2.47k | 21.51 | 2.54 | -- | 6.16 | 1.18 | 1.18 | 4.11 | 9.95 | 0.36 | 2.68 | 6.66 | 727,792.60 | 10.31 | -- | 11.11 | -- | 39.78 | -- | 28.63 | -- | 5.51 | -- | 0.0551 | -- | -18.34 | -- | -23.51 | -- | -- | -- |
| Heilongjiang ZBD Pharmaceutical Co Ltd | 2.73bn | 511.96m | 11.16bn | 2.55k | 21.76 | 1.42 | -- | 4.09 | 0.5447 | 0.5447 | 2.90 | 8.35 | 0.2186 | 1.58 | 0.8134 | 1,071,832.00 | 4.06 | 3.48 | 5.61 | 4.78 | 46.09 | 38.93 | 18.56 | 10.08 | 2.35 | -- | 0.2862 | 27.18 | -25.50 | 2.45 | 155.00 | 0.4417 | -25.68 | 4.05 |
Data as of Jun 14 2024. Currency figures normalised to Sansure Biotech Inc's reporting currency: Chinese Yuan Renminbi CNY
7.36%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| E Fund Management Co., Ltd.as of 31 Dec 2023 | 18.38m | 3.12% |
| GF Fund Management Co., Ltd.as of 31 Dec 2023 | 5.51m | 0.94% |
| Bosera Asset Management Co., Ltd.as of 31 Dec 2023 | 5.35m | 0.91% |
| Penghua Fund Management Co., Ltd.as of 31 Dec 2023 | 3.19m | 0.54% |
| Lion Fund Management Co., Ltd.as of 31 Dec 2023 | 2.77m | 0.47% |
| China Southern Asset Management Co., Ltd.as of 31 Dec 2023 | 2.20m | 0.38% |
| Maxwealth Fund Management Co., Ltd.as of 31 Dec 2023 | 1.94m | 0.33% |
| Fullgoal Fund Management Co., Ltd.as of 31 Dec 2023 | 1.69m | 0.29% |
| Wanjia Asset Management Co., Ltd.as of 31 Dec 2023 | 1.18m | 0.20% |
| Da Cheng Fund Management Co., Ltd.as of 31 Dec 2023 | 1.12m | 0.19% |
More ▼
Data from 31 Dec 2023 - 06 Jun 2024Source: FactSet Research Systems Inc.
